RJA
AERI

Raymond James & Associates’s Aerie Pharmaceuticals AERI Stock Holding History

Raymond James & Associates’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-23,800
Closed -$74K – 3428
2016
Q4 		$74K Hold
23,800
– – ﹤0.01% 3061
2016
Q3 		$102K Buy
+23,800
New +$525K ﹤0.01% 2996

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Raymond James & Associates's AERI Position: Q3 2021 in Review

Raymond James & Associates sold out of Aerie Pharmaceuticals (AERI) in Q3 2021, closing a stake of 42,662 shares — an estimated $683K sold.

Raymond James & Associates first reported a position in AERI in Q3 2014 and held it in 25 quarters. The position peaked at $4.41M in Q3 2016. 137 funds tracked by Wall St. Rank hold AERI as of Q3 2021.

  • Raymond James & Associates reported no remaining Aerie Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 42,662 Aerie Pharmaceuticals shares in Q3 2021, an estimated $683K.
  • Raymond James & Associates first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 25 quarters.
  • Raymond James & Associates's Aerie Pharmaceuticals position peaked at $4.41M in Q3 2016.
  • 137 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.